Tersolisib for neoplasm metastasis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 15 Sep 2025: Trial registered, NCT07174336
  2. 22 Dec 2025: Trial started, NCT07174336

The trials

NCT07174336: A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

State
Under way
Phase
Phase 3
People
800 planned
Started
22 Dec 2025
Primary completion
May 2029
Arms
LY4064809 + CDK4/6 Inhibitor + Endocrine Therapy (ET) (Part 1), LY4064809 + CDK4/6 Inhibitor + Endocrine Therapy (ET) (Part 2)
Results
None posted
  1. 15 Sep 2025: Trial registered
  2. 22 Dec 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.